Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY„¢ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that members of its management team will present at the following upcoming conferences:
Cowen & Company 39th Annual Health Care Conference Date: Wednesday, March 13, 2019 Presentation Time: 10:40 a.m. ET Speaker: Mark Iwicki, Chairman, President and Chief Executive Officer Location: Boston, MA
Oppenheimers 29th Annual Healthcare Conference Date: Wednesday, March 20, 2019 Presentation Time: 8:35 a.m. ET Speaker: Todd Bazemore, Chief Operating Officer Location: New York, NY
To access a live webcast and subsequent archived recording of each presentation, please visit the Investors & Media section on the Kala website at http://kalarx.com
About Kala Pharmaceuticals, Inc.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFYTM mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in recently approved INVELTYSTM for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease, for which a New Drug Application (NDA) has been filed with the United States Food and Drug Administration (FDA) and a target action date under the Prescription Drug User Fee Act (PDUFA) has been set for August 15, 2019.